Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Unimpressive Q3 - Still Waiting

<< Previous

Bullboard Posts

Next >>

Post by longrun86on Nov 07, 2024 9:59am

151 Views

Post# 36300875

Unimpressive Q3 - Still Waiting

Tales of glory will most certainly not be written about Knight's Q3 performance.

I am still holding my shares.

I am looking forward to the day when it finally signals that it will be a profitable business and generate returns on shareholder capital as measured in Net Income.

It feels like it is coming soon but I've also been feeling this way since 2022!

LR

<< Previous

Bullboard Posts

Next >>

First Helium advances winter drilling program with Leduc Anomaly test well